Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial

Neurology

Volumn 86, Issue 22, 2016, Pages 2071-2076

  Sano, Mary ^a,b   Aisen, Paul S ^c   Andrews, Howard F ^d,e   Tsai, Wei Yann ^f   Lai, Florence ^g   Dalton, Arthur J ^h,i  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^e Department of Psychiatry ^*  (United States)

^f Columbia University College of Physicians and Surgeons ^*  (United States)

^g McLean Hospital   (Australia)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN E; PLACEBO; NOOTROPIC AGENT;

ADULT; AGING; ALLELE; APOLIPOPROTEIN E EPSILON 4 GENE; ARTHRALGIA; ARTICLE; BRIEF PRAXIS TEST; COGNITION; CONTROLLED STUDY; DEATH; DEMENTIA; DEPRESSION; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DOWN SYNDROME; DRUG SAFETY; FEMALE; GENE; GLOBAL CHANGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MENTAL DETERIORATION; MIDDLE AGED; MULTICENTER STUDY; NEUROLOGIC EXAMINATION; PATHOLOGICAL CRYING; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; CLINICAL TRIAL; COGNITIVE DYSFUNCTION; COMPLICATION; GENETICS; MORTALITY; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; TREATMENT FAILURE;

ADMINISTRATION, ORAL; APOLIPOPROTEINS E; COGNITIVE DYSFUNCTION; DEMENTIA; DOUBLE-BLIND METHOD; DOWN SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; TREATMENT FAILURE; VITAMIN E;

EID: 84973534387     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002714     Document Type: Article

References (36)

1. Malamud N. Neuropathology of organic brain: syndromes associated with aging. In: Gaitz CM, editor. Aging and the Brain. 3rd ed. New York: Plenum; 1972:63-87.
2. Mann DM, Yates PO, Marcyniuk B. Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol 1984; 10:185-207.
3. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 1985;17:278-282.
4. Lai F, Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 1989;46:849-853.
5. Janicki MP, Dalton AJ. Prevalence of dementia and impact on intellectual disability services. Ment Retard 2000;38:276-288.
6. Janicki MP, Dalton AJ, Henderson CM, Davidson PW. Mortality and morbidity among older adults with intellectual disability: health services considerations. Disabil Rehabil 1999;21:284-294.
7. Hanney M, Prasher V, Williams N, et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOES): A randomized, double-blind, placebo-controlled trial. Lancet 2012;379:528-536.
8. Kishnani PS, Sommer BR, Handen BL, et al. The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. Am J Med Genet A 2009;149A:1641-1654.
9. Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol 1996;149:21-28.
10. Smith MA, Perry G, Richey PL, et al. Oxidative damage in Alzheimer's. Nature 1996;382:120-121.
11. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 1998;19:33-36.
12. Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995;378:776-779.
13. Busciglio J, Pelsman A, Wong C, et al. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 2002;33:667-688.
14. Brugge K, Nichols S, Saitoh T, Trauner D. Correlations of glutathione peroxidase activity with memory impairment in adults with Down syndrome. Biol Psychiatry 1999;46: 1682-1689.
15. Pratico D, Iuliano L, Amerio G, et al. Down's syndrome is associated with increased 8, 12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol 2000;48:795-798.
16. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-1222.
17. Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA 2014;311:33-44.
18. Petersen RC, Thomas RG, Grudman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-2389.
19. Sano MC, Aisen PS, Dalton AJ, Andrews HF, Tsai WY; the International Down Syndrome Alzheimer's Disease Consortium. Assessment of aging individuals with Down syndrome in clinical trials: results of baseline measures. J Policy Pract Dev Disabil 2005;2:126-138.
20. Lott IT, Doran E, Nguyen VQ, Tournay A, Movsesyan N, Gillen DL. Down syndrome and dementia: seizures and cognitive decline. J Alzheimers Dis 2012;29:177-185.
21. Aisen PS, Dalton AJ, Sano MC, Lott IT, Andrews HF, Tsai WY. Design and implementation of a multicenter trial of vitamin E in aging individuals with Down syndrome. Policy Pract Intellect Disabilities 2005;2:86-93.
22. Dalton A, Fedor B. Dyspraxia Scale for Adults With Down Syndrome. Staten Island, NY: NYS Institute for Basic Research in Developmental Disabilities; 1997.
23. Schupf N, Kapell D, Lee JH, et al. Onset of dementia is associated with apolipoprotein E e4 in Down syndrome. Ann Neurol 1996;40:799-801.
24. Lai F, Kammann E, Rebeck GW, Anderson A, Chen Y, Nixon RA. APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome. Neurology 1999;53:331-336.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
26. International Classification of Diseases, Ninth Revision, Clinical Modification. Available at: http://www. who. int/ classifications/icd/en/. Accessed April 27, 2016.
27. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford, UK: Clarendon Press; 1989.
28. Bruce AJ, Malfroy B, Baudry M. b-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger. Proc Natl Acad Sci USA 1996;93:2312-2316.
29. Tomiyama T, Shoji A, Kataoka K, et al. Inhibition of amyloid b protein aggregation and neurotoxicity by rifampicin: its possible function as a hydroxyl radical scavenger. J Biol Chem 1996;271:6839-6844.
30. Galasko DR, Peskind E, Clark CM, et al; for the Alzheimer's Disease Cooperative Study. Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 2012; 69:836-841.
31. Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DL. Down syndrome and dementia: A randomized, controlled trial of antioxidant supplementation. Am J Med Genet A 2011;155A:1939-1948.
32. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma R, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-47.
33. Zigman WB, Schupf N, Sersen E, Silverman W. Prevalence of dementia in adults with and without Down syndrome. Am J Ment Retard 1996;100:403-412.
34. Holland AJ, Hon J, Huppert FA, Stevens F, Watson P. Population-based study of the prevalence and presentation of dementia in adults with Down's syndrome. Br J Psychiatry 1998;172:493-498.
35. Tyrrell J, Cosgrave M, McCarron M, et al. Dementia in people with Down's syndrome. Int J Geriatr Psychiatry 2001;16:1168-1174.
36. Devenny DA, Krinsky-McHale SJ, Sersen G, Silverman WP. Sequence of cognitive decline in dementia in adults with Down's syndrome. J Intellect Disabil Res 2000;44:654-665.